Hetero Labs Limited Moxifloxacin Export Data — India (DGFT 2022–2026)

Name: Hetero Labs Limited Moxifloxacin Export Records India — #13 Exporter, 7 Shipments, $260.9K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-04-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Moxifloxacin

India Pharmaceutical Trade Intelligence

$32.8M336 Suppliers137 CountriesHS 30049099

ExportsIndia → NIGERIA44.8%India → UNITED STATES17.5%

ImportsUNITED STATES → India$160.3B BRAZIL → India$30.7B

#1 Buyer: NATIONAL TUBERCULOSIS

Hetero Labs Limited — Moxifloxacin Exporter #13 | $260.9K Trade Value | TransData Nexus | TransData Nexus

Hetero Labs Limited — Moxifloxacin Exporter Profile

Indian Pharmaceutical Exporter · #13 for Moxifloxacin · $260.9K export value · DGFT Verified

Hetero Labs Limited is the #13 Indian exporter of Moxifloxacin with $260.9K in export value and 7 verified shipments. Hetero Labs Limited holds a 0.8% market share in Moxifloxacin exports across 3 countries. The company exports 46 pharmaceutical products worth $319.3M across 18 therapeutic categories.

Hetero Labs Limited — Moxifloxacin Export Profile: Buyers & Destinations

Hetero Labs Limited Moxifloxacin export treemap — buyers and destination countries | TransData Nexus

Where Does India Export Moxifloxacin?

Country	Value	Shipments	Share
UNITED STATES	$5.8M	178	35.1%
NIGERIA	$2.8M	55	16.8%
NETHERLANDS	$1.7M	46	10.2%
THAILAND	$1.0M	38

Who Are the Top Buyers of Moxifloxacin from India?

Buyer	Country	Value	Orders
MYLAN INSTITUTIONAL INC 2898	UNITED STATES	$742.1K	16
AUROLOGISTICS LLC, (AUROBINDO PHARM	UNITED STATES	$650.0K	13
AUROBINDO PHARMA USA., INC,	UNITED STATES	$442.3K	9
TOPONE DISTRIBUTION LTD	CAMBODIA	$389.9K	14
I+SOLUTIONS	NETHERLANDS	$383.6K	9
J. KNIPPER & COMPANY	UNITED STATES	$381.1K	12
I+ SOLUTIONS,	NETHERLANDS	$350.0K	7
NORTHSTAR DISTRIBUTION CENTER 8912	UNITED STATES	$300.0K	6
MICRO NOVA PHARMACEUTICALS IND	NIGERIA	$300.0K	6
NATIONAL TUBERCULOSIS AND LEPROSY	NIGERIA	$100.0K	2

India's Moxifloxacin is purchased by 731 buyers worldwide. The top buyer is MYLAN INSTITUTIONAL INC 2898 (UNITED STATES), followed by AUROLOGISTICS LLC, (AUROBINDO PHARM and AUROBINDO PHARMA USA., INC,.

How Does Hetero Labs Limited Compare to Nearest Moxifloxacin Exporters?

Exporters ranked immediately above and below #13 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
10	MANKIND PHARMA LIMITED	$452.0K	11	2	$41.1K
11	SUN PHARMACEUTICAL INDUSTRIES LIMITED	$401.3K	15	6	$26.8K
13	HETERO LABS LIMITED ★	$260.9K	7	3	$37.3K
14	INDOCO REMEDIES LIMITED	$239.8K	18	8	$13.3K
15	ALVITA PHARMA PRIVATE LIMITED	$235.8K	8	1	$29.5K

Hetero Labs Limited ranks #13 among 336 Indian Moxifloxacin exporters. Average shipment value of $37.3K compared to the market average of $42.4K. The closest competitors by value are MANKIND PHARMA LIMITED and SUN PHARMACEUTICAL INDUSTRIES LIMITED.

Which Indian Ports Ship Moxifloxacin Exports?

Port	Shipments	% Share
SAHAR AIR	311	12.9%
SAHAR AIR CARGO ACC (INBOM4)	263	10.9%
DELHI AIR CARGO ACC (INDEL4)	152	6.3%
DELHI AIR	132	5.5%
NHAVA SHEVA SEA (INNSA1)	126	5.2%
Bombay Air	119	4.9%
CHENNAI AIR	111	4.6%
CHENNAI AIR CARGO ACC (INMAA4)	93	3.9%

Geopolitical & Trade Policy Impact on Hetero Labs Limited's Moxifloxacin Exports

The current geopolitical climate presents both challenges and opportunities for Hetero Labs Limited. The Israel-Iran tensions have led to increased risks in the Red Sea shipping routes, prompting major shipping lines to implement 'Emergency Risk Surcharges' ranging from $250 to $500 per TEU. This escalation in shipping costs directly impacts Indian pharmaceutical exporters like Hetero, potentially eroding profit margins and necessitating strategic adjustments in logistics and pricing strategies.

Conversely, the U.S.-China trade tensions have created openings for Indian pharmaceutical companies. The U.S. has imposed tariffs as high as 245% on APIs from certain countries, leading to a reshoring of pharmaceutical manufacturing. Indian firms, including Hetero, have responded by investing in U.S. facilities, with outbound foreign direct investment estimated between $500-700 million during the partial FY 2025-26. This strategic move not only circumvents tariffs but also strengthens Hetero's presence in the lucrative U.S. market.

The recent India-European Union Free Trade Agreement (FTA), concluded in January 2026, eliminates tariffs on Indian pharmaceuticals entering the EU. This development enhances Hetero's competitiveness in the European market, providing a significant boost to its export potential. However, compliance with the EU's Falsified Medicines Directive remains imperative, necessitating stringent quality controls and traceability measures to maintain market access.

Hetero Labs Limited — Regulatory Compliance & Quality Standards

Regulatory compliance is paramount for Hetero's sustained success in international markets. In October 2025, the U.S. Food and Drug Administration (FDA) issued a Form 483 to Hetero's Nakkapalli facility in Andhra Pradesh, citing six major compliance lapses, including quality control deficiencies and improper documentation practices. Such observations can jeopardize Hetero's ability to supply APIs and antiretroviral drugs to the U.S. market, underscoring the critical need for rigorous adherence to Good Manufacturing Practices (GMP) and prompt corrective actions to address regulatory concerns.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Moxifloxacin shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Hetero Labs Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 137+ countries, 731+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Moxifloxacin

Moxifloxacin

Hetero Labs Limited — Moxifloxacin Exporter Profile

Hetero Labs Limited — Moxifloxacin Export Profile: Buyers & Destinations

Where Does India Export Moxifloxacin?

Who Are the Top Buyers of Moxifloxacin from India?

What Is India's Total Moxifloxacin Export Value and How Much Does Hetero Labs Limited Contribute?

What Is the Average Shipment Value for Hetero Labs Limited's Moxifloxacin Exports?

How Does Hetero Labs Limited Compare to Other Indian Moxifloxacin Exporters?

Regulatory Requirements: Exporting Moxifloxacin to Key Markets

United States — FDA

Nigeria — NAFDAC

How Does Hetero Labs Limited Compare to Nearest Moxifloxacin Exporters?

Which Indian Ports Ship Moxifloxacin Exports?

Geopolitical & Trade Policy Impact on Hetero Labs Limited's Moxifloxacin Exports

Hetero Labs Limited — Regulatory Compliance & Quality Standards

About Hetero Labs Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Moxifloxacin Export Data from Hetero Labs Limited

Moxifloxacin Stats

Company Overview

Top Products by Hetero Labs Limited

Related Analysis

Need Detailed Export Data?

Data Source